<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01986049</url>
  </required_header>
  <id_info>
    <org_study_id>IRBNet # 367320</org_study_id>
    <nct_id>NCT01986049</nct_id>
  </id_info>
  <brief_title>Transversus Abdominis Plane (TAP) Block for Post Caesarian Pain</brief_title>
  <acronym>TAPBlock</acronym>
  <official_title>Phase 3 Study Comparing Transversus Abdominis Plane Block After Caesarian Section Usin Bupivacaine 0.5% vs. Bupivacaine 0.25% vs. Placebo (Normal Saline).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Presbyterian Brooklyn Methodist Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Presbyterian Brooklyn Methodist Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adding TAP block with Bupivacaine may decrease the use of PCA bolus use after caesarean&#xD;
      section for pain relief.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants in the study will be randomized to TAP block with 0.5% or 0.25% bupivacaine or&#xD;
      with placebo (normal saline).&#xD;
&#xD;
      The number of PCA bolus used within 24 hours post cesarean section will be compared between&#xD;
      the groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    We never collected data or started to recruit participants&#xD;
  </why_stopped>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Transversus Abdominis Plane (TAP) Block for Post Caesarean Pain</measure>
    <time_frame>The first post operative 24 hours</time_frame>
    <description>In Patient Controlled analgesia (PCA) system, the patient receives a preset dose of morphine by pressing a button on a computerized pump that is connected to an IV catheter. With PCA the patient may receive a small continuous flow of morphine and add more morphine as needed to provide a more constant level of comfort. In this study, we will compare the number of PCAs used by the participants in each arm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in the pain score as measured by Visual Analog Scale (VAS)</measure>
    <time_frame>The first post operative 24 hours</time_frame>
    <description>Visual Analog Scale (VAS) is a numeric scale to measure the pain intensity from 0 to 10, where 0 = no pain, (1-3) = mild pain, (4-6) = moderate pain, and (7-10) = severe pain. The worst imaginable pain = 10</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Obstetrical Complications From Sedation During Parturition</condition>
  <arm_group>
    <arm_group_label>Bupivicaine 0.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug Bupivacaine 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivicaine 0.25%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug Bupivacaine 0.25%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline Normal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivicaine</intervention_name>
    <arm_group_label>Bupivicaine 0.25%</arm_group_label>
    <arm_group_label>Bupivicaine 0.5%</arm_group_label>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy pregnant (ASA II) patients presenting for planned Cesarean delivery at New York&#xD;
        Methodist Hospital under combined spinal epidural anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  They are unable or are unwilling to take part in the study&#xD;
&#xD;
          -  They have a history of allergy to any of the medications to be used in the study&#xD;
&#xD;
          -  They have a history of drug abuse or chronic pain or opioid use&#xD;
&#xD;
          -  They weigh less than 60kg&#xD;
&#xD;
          -  They have a multiple gestation, placental disease, preeclampsia other disease of&#xD;
             pregnancy&#xD;
&#xD;
          -  They have a contraindication to neuraxial anesthesia (i.e., bleeding problems,&#xD;
             bacteremia, etc.)&#xD;
&#xD;
          -  They are unable to understand instructions or questions related to the study&#xD;
&#xD;
          -  ASA III or IV&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Weinberg, MD</last_name>
    <role>Study Director</role>
    <affiliation>New York Methodist Hospital Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New Yoyk Methodist Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 7, 2013</study_first_submitted>
  <study_first_submitted_qc>November 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2013</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York Presbyterian Brooklyn Methodist Hospital</investigator_affiliation>
    <investigator_full_name>Joel Yarmush</investigator_full_name>
    <investigator_title>Anesthesiologist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

